This isn't going to help On October 10, 2018, TearLab Corporation (the “Company”) issued a press release announcing the U.S. Food and Drug Administration (“FDA”) has determined that the TearLab Discovery TM MMP-9 test, has not met the criteria for substantial equivalence based upon data and information submitted by TearLab in its 510(k) submission. A copy of this press release is attached thereto as Exhibit 99.1 and is hereby incorporated by reference herein.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.